Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 7/20 | 0.37 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2220648 | 1.00 | MAP4K4 (0.45) | MAP4K4GPR119TRPV1SUV39H2HDAC1 | |
| SCHEMBL1102299 | 0.83 | SMO (0.51) | MAP4K4GPR119TRPV1SUV39H2HDAC1 | |
| SCHEMBL4166702 | 0.83 | SMO (0.51) | MAP4K4GPR119TRPV1SUV39H2HDAC1 | |
| SCHEMBL2277210 | 0.83 | SMO (0.51) | MAP4K4GPR119TRPV1SUV39H2HDAC1 | |
| SCHEMBL2212683 | 0.83 | SMO (0.43) | TRPV1SMO | |
| SCHEMBL2217412 | 0.81 | SMO (0.55) | MAP4K4GPR119HDAC1SMO | |
| SCHEMBL2217409 | 0.81 | SMO (0.55) | MAP4K4GPR119HDAC1SMO | |
| SCHEMBL5240108 | 0.80 | MAP4K4 (0.50) | MAP4K4GPR119TRPV1SUV39H2HDAC1 | |
| SCHEMBL12435071 | 0.79 | SMO (0.56) | MAP4K4GPR119SMO | |
| SCHEMBL31105008 | 0.77 | MAP4K4 (0.50) | MAP4K4GPR119TRPV1SUV39H2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102216292-B | Tetrasubstituted pyridazines HEDGEHOG pathway antagonists | LILLY CO ELI | 2014-08-13 | — | — | CN | disclosed |
| EP-2358703-B1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | LILLY CO ELI (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8445493-B2 | Tetrasubstituted pyridazines hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445493-B2 | Tetrasubstituted pyridazines hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445493-B2 | Tetrasubstituted pyridazines hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| CN-102216292-A | Tetrasubstituted pyridazines HEDGEHOG pathway antagonists | LILLY CO ELI | 2011-10-12 | — | — | CN | disclosed |
| US-20110178093-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178093-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178093-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178093-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | SMO, SHH, GLI1 | MAP4K4 935/4885GPR119 984/4885TRPV1 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.